Lance Mynderse, MD
Urology · Rochester, MNNPI 1700865938
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,500 of the $3,699 with a category attached, or 67.6%. Boston Scientific accounts for 78.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $2,692 and has fallen 93.0% since, to $188 in 2025.
Across 14 payments — averaging $264.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Insightec,ltd$253
- Profound Medical Corp.$201
- Photocure Inc$169
- Angiodynamics, Inc.$153
- AstraZeneca$35
Across 6 payments — averaging $13,312 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insightec,ltd$74K
- Boston Scientific$6K
What the payments were for
- Consulting fees$2,50068%
- Travel & lodging$2537%
- Food & beverage$91125%
- Education$351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $2,888 |
| Insightec,ltd | 1 | $253 |
| Profound Medical Corp. | 3 | $201 |
| Photocure Inc | 2 | $169 |
| Angiodynamics, Inc. | 1 | $153 |
| AstraZeneca | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPACEOAR VUE$2,601
- Exablate$253
- Nanoknife$153
- SpaceOAR VUE System - 10mL$105
How this compares
$3,699 in reported general payments places this provider in the 75th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 11 | $6,013 |
| Tamsulosin Hcl | 15 | $197 |
| Finasteride | 27 | $83 |
| Cefdinir | 12 | $35 |
Paid to pharmacies, not to this prescriber.
Other urology in Rochester
- Jonathan WarnerRochester$144K
- Tobias KohlerRochester$89K
- Stephen BoorjianRochester$61K
- Robert KarnesRochester$29K
- Kevin WymerRochester$16K
- Paras ShahRochester$14K
- Matthew ZiegelmannRochester$9K
- Meghan CooperRochester$8K
- Sevann HeloRochester$6K
- Brian LinderRochester$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.